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Introduction
T he treatment of craniopharyngioma has long been con-sidered difficult. Although complete removal of tumor
is associated with a favorable outcome, mortality and morbidity
increases with attempts at radical surgery32). Even with complete
tumor removal, recurrence rate is 10 to 18% after 2.5 to 10
years and continued tumor growth after partial removal is
reported to be 63 to 90%32). It is also known that morbidity
and mortality increases with subsequent attempts at radical
surgery32). After the introduction of gamma knife radiosurgery
(GKS), it became an effective and less invasive tool for neu-
rosurgeons against benign and malignant tumors. First GKS
for craniopharyngioma was done by Backlund et al in 19722)
and following studies on GKS for remnant craniopharygiomas
after surgical removal have been reported8,10,19,21,22,28,32). Less
radiation related complications and good tumor regression
rate make surgeons less aggressive on surgical removal and
give chance for multimodal treatment.
Our study was to assess the effectiveness of GKS for cran-
iopharygiomas on tumor control and possibly set a proper
radiation dose for tumor control with utmost preservation
of adjacent structures. 
Materials and Methods
F rom period of May 1993 to November 2002, total of14 patients received GKS (201-source cobalt-60 gamma
unit, Elekta Instruments, Stockholm, Sweden) with 13 patients
receiving once and 1 patient receiving three times. Mean age
of patients at time of GKS was 30.3 years (4.4~62.9 years).
Five patients were male and 9 were female. All patients recei-
ved surgical removal before GKS for histological confirmation
and tumor debulking. All except one patient received cranio-
tomy for removal of tumor and one exception being trans-
sphenoidal approach. All MR imaging for remnant or recurred
tumor were converted using GammaPlan software where
tumor volumes were calculated. Enhanced T1 weighted MR
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images were used to delineated tumor margin. All measurements
were performed by one investigator (Y. K.). Radiologic outcomes
were categorized into three groups : decreased (0~80% of
original tumor volume), static (80~120%), and increased
(more than 120% of original tumor volume). Tumor was
considered as recurred if clinical symptom and sign worsened
even when increase in tumor volume did not exceed 120%. 
Clinical and imaging follow up
Visual and endocrinologic evaluations were routinely done
preoperatively. Visual evaluation included visual acuity and
field test (Humphrey perimetry) and endocrinologic evaluation was
done with combined pituitary function test. Postoperatively,
all patients returned for clinical evaluation every month. Patients
were questioned subjectively for postoperative changes in vision
and hormonal symptoms. 
Mean follow up duration was 48.0 months (range 11.3~
123.6 months). This study is a follow up version of prelim-
inary study reported at 2001 with added patients and longer
follow up period7).
Results
Radiological Outcome after GKS
Total of 16 procedures were done
in 14 patients. Tumor volume ranged
from 0.4cm3 to 18.0cm3 (mean 3.6
cm3). Mean margin dose was 12.2
Gy (range 8~22.4Gy) and dose to
optic chiasm was mean 7.9Gy (range
4~11Gy). 
Of the 16 tumors treated with GKS,
12(75%) decreased in size (0~80%
of the original tumor volume). Two
(12.5%) of the 16 tumors were con-
sidered static (80~120% of the ori-
ginal tumor volume) thus the control
rate (decreased and static volume)
was 87.5% (14 of 16 tumors). For
one patient who received GKS 3
times, the first was considered recu-
rrent and the rest were considered
controlled.
For the 14 tumors where tumor
control was achieved, mean tumor
volume was 3.8cm3 (range 0.6~18.0
cm3). For the 2 recurred tumors,
mean tumor volume was 1.6cm3
(0.4 and 2.8cm3). Comparing the
mean margin dose of controlled and
recurred tumor, they were 11.8 and 13.3Gy respectively. For
the two recurred cases, both tumors were solid in nature. As
for the controlled cases, 4 were cystic and the rest were either
solid or mixed. Mean follow up period for the controlled cases
was 49.1 months (range 11.3~98.0 months) and for the recurred
cases, 106.9 months (range 90.2~123.6 months). Time interval
to recurrence for the two cases were 57.6 and 123.6 months
(Table 1). Statistical significance be-tween the tumor controlled
group and recurred group was not tested due to small size
of patient population. Tumor volume, radiation dose, and
imaging outcome are summarized in Table 2. 
One of the two recurred cases was a 15 year old female who
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Table 1. Comparison between controlled cases and recurred cases
Parameters Controlled cases Recurred cases
Number of cases 14 2
Target volume (cm3) 0.6-18.1 (mean 13.8) 10.4/112.8 (mean 111.6)
Margin dose (Gy) 1.8-22.4 (mean 11.8) 114/112.6 (mean 113.3)
PreGKS* image Cystic 4, solid 6, mixed 4 Solid 2
Follow-up duration (months) 11.3-98.0 (mean 49.1) 90.2/123.6 (mean 106.9)
Recurrence (months) - 57.6/123.6 (mean 190.6)
*PreGKS : preoperative to Gamma knife surgery
Table 2. Summary of cases                     
Patient Age/ PreGKS* Target Margin dose
Results
F/U duration
PreGKS* image
No sex treatment volume(cm3) (Gy) (months)
11† 44/F C/R*** 43.2 48.4 Shrunk 439.9 Cystic
12† 47/M C/R*** 42.4 48.5 Shrunk 498.0 Solid
13† 15/F C/R*** 40.4 14.4 Recurred 123.6 Solid
14† 16/M TSA*** 18.0 48.5 Shrunk 497.6 Solid
15† 63/F C/R*** 40.7 15.4 Static 411.3 Mixed
16† 30/M C/R*** 2.8/2.9/0.6 12.6/22.4/14.5 recur/shrunk/static 90 /60 /25 Solid/Solid/Solid
17† 48/F C/R *** 46.3 11.5 Shrunk 445.1 Mixed
18† 15/F C/R** * 41.8 10.4 Shrunk 436.9 Solid
19† 43/F C/R*** 42.1 10.4 Shrunk 439.8 Solid
10† 38/F C/R*** 40.6 13.4 Shrunk 434.5 Cystic
11† 23/M C/R *** 48.6 11.4 Shrunk 421.4 Mixed
12† 44/M C/R*** 40.6 14.4 Shrunk 417.3 Cystic
13† 44/F C/R*** 42.9 10.4 Shrunk 411.9 Cystic
14† 38/F C/R*** 41.6 49.4 Shrunk 414.4 Mixed
*PreGKS : preoperative to Gamma knife surgery, **C/R : Craniotomy and tumor removal, ***TSA : Trans-sphenoidal
approach, †GKS was done 3 times where each procedure is divided by a slash(/)
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Fig. 1. Serial T1 weighted coronal magnetic resonance(MR) images of 15 a year-old woman with
short stature. (A) Preoperative MR image showing a 9X9mm sized solid craniopharyngioma. (B)
Postoperative MR image showing remnant mass (C) MR image taken 10 years after GKS showing 2
X2.5cm cystic recurrent tumor.
had visited our clinic for short stature. Evaluation revealed
panhypopituitarism and a 9×9mm suprasellar tumor on
her brain MRI. She received craniotomy for removal of tu-
mor where histologic confirmation for craniopharyngioma
was made and followed by GKS. She had not visited our clinic
since then and had been follow up lost for 10 years. She re-
visited our clinic 2 years ago and had MRI taken which re-
vealed a 2×2.5cm sized cystic recurrent mass (Fig. 1). She
underwent another surgical removal of tumor. 
Another case of recurrence was with a 30 year old male pa-
tient who had progressive bilateral vision loss. His MRI re-
vealed 13×19mm sized cranioph-
aryngioma and underwent surgical
removal (Fig. 2). His postoperative
MRI showed 2×2mm sized remnant
mass and GKS was done. Fourteen
months after GKS, recurrent mass
was found adjacent to the optic ch-
iasm. It was not thought to be a rec-
urrence after GKS since no mass was
seen adjacent to optic chiasm at pos-
toperative MRI and radiation dose
was not included on optic chiasm.
Second GKS was done at newly
found mass. Forty three months after
the 2nd GKS (which is 57 months
after the 1st GKS), a recurrent mass
was found in the area of initial rem-
nant tumor at follow up MRI. Third
GKS was done and no recurrence
is yet found at 25 months follow up.
Visual and Endocrinologic
Outcome after GKS
Eight of 14 (57%) patients had
preoperative visual impairment. In
case where tumor was attached or
adjacent to the optic apparatus, ma-
rgin dose was restricted to 8 or 8.5
Gy (Case 1, 2, and 4). However,
when patient’s preoperative visual
loss was severe, vision sparing was
no longer of concern and dose as
high as 22.4Gy was used for better
tumor control (Case 6). No patient
had deterioration of vision posto-
peratively. 
Seven of 14 (50%) patients had
preoperative hormonal insufficiency.
Hormonal replacement was done
for these patients with 7.5mg methyl prednisolon, 100ug lev-
othyroxine sodium, and 0.05mg desmopressin preoperatively.
Hormonal status remained stable in all patients including
patients without preoperative hormonal deficiency.
Volume response after GKS
Volume response of tumor after GKS varied among cases.
Ten (62.5%) had progressive volume reduction (＜80% of
original volume), while two (Case 1 and case 14) had transient
volume expansion followed by marked reduction at next follow
up imaging (Fig. 3). For case 1, volume expansion began as
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Fig. 2. Serial T1 weighted coronal
magnetic resonance(MR) images
of a 30-year-old man with pr-
ogressive bilateral visual disturb-
ance. (A) Preoperative MR image
showing a 13X19mm sized solid
craniopharyngioma. (B) Postop-
erative MR image showing a 2X
2mm remnant mass. (C) Post ga-
mma knife surgery(GKS) 14 months
MR image showing recurrent mass
adjacent to the optic chiasm and 2nd GKS was done. (D) MR image taken 43 months after 2nd GKS
where recurrent tumor is found in area of initial remnant tumor. 3rd GKS was done. (E) No tumor is seen
after 25 months follow up after the 3rd GKS. 
A B C
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Fig. 3. Serial T1 weighted coronal magnetic resonance(MR) images of a 38-year-old woman with visual
disturbance. (A) Preoperative MR image showing a craniopharyngioma with mixed cystic and solid nature.
(B) Postoperative MRI showing remnant mass. (C) Postoperative gamma knife surgery(GKS) MR image
treated with margin dose of 9Gy. (D) PostGKS 3 months MR image showing typical volume expansion
mainly cystic enlargement. (E) & (F) PostGKS 5 months and 8 months follow up MR image with regression of
cystic component with stabilized size of solid mass. 
early as 3rd month and shrunk dramatically at 4th follow up
month. In case 14 however, the volume expansion was found
at 6th follow up month and expansion lasted until 11th month
where tumor markedly shrunk at next follow up imaging. 
Discussion
Treatment modalities
Adjuvant therapy such as radiation therapy(RT) has shown
good results. 10-year survival rates of 81 to 91% after subtotal
removal followed by RT has been reported15,29) and adjuvant
radiotherapy has been the preferred practice for neurosurgeons.
However, radiotherapy is not without hazard. Radiation nec-
rosis, optic neuritis, malignancies, and cognitive disturbances
in young children following RT is reported to be 6 to 18% of
patients6,29). Tumor recurrence is also reported to be 14 to 22%
5 to 10 years after RT12,13,25,29) and mortality rate of patients
suffering recurrence after RT is 83 to 100%12,25,29,30,34,35). 
Alternative treatments such as neuroendoscopy and intra-
cavitary brachytherapy have been introduced to decrease surg-
ery related mortality and morbidity2,3,16,23,37). Intracavitary ra-
diation and chemotherapy can be effective modality for cystic
tumors but it also harbors considerable hazards such as visual
deterioration and tumor regression may not be satisfactory5,24,26,33).
Our institution has discarded the use of intracystic treatment
and radiation therapy and substituted with surgical removal
of tumor plus GKS for remnant or recurred cases. 
Tumor control and associated factors in GKS treated 
craniopharyngiomas
On tumor control of craniopharyngiomas after GKS, much
have been mentioned on nature of tumor (whether solid or
cystic), treated tumor volume, and radiation dose to tumor,
but these characteristics are yet to be statistically proven and
need prospective or controlled study with bigger patient pop-
ulation. Attempts at justifying radiosurgery for craniopharyng-
iomas have started since Backlund2 and subsequent reports
followed supporting its effectiveness. Mokry et al22) reported
tumor control rate of 56% and Ko-
bayashi et al19) reported a much
improved tumor control of 85%
(Table 3). Although tumor control
rate tends to fall with longer follow
up period, short term treatment
failure of GKS is often observed
in cystic tumors1,17). Backlund et
al2) suggested the use of intracystic
brachytherapy for cystic compon-
ents, and Ulfarsson’s study32) also
observed high rate of cystic enlar-
gement after GKS. Although statistical difference is yet to be
proven, many institutions defer the use of GKS in cystic cran-
iopharyngiomas. Cystic tumors are result of diffusion of plasma
from the capillaries of the tumor and Gardner16) suggested
inability of brain getting rid of this fluid. In our study, the two
recurred cases were both solid tumor in nature and we inferred
that cystic recurrence can be minimized by surgically removing
the tumor cyst and treating rest of the tumor with GKS. The
principle is not just to puncture the cyst but to remove as much
cyst wall as possible. Four cystic tumors and four mixed tumors
did not show recurrence as long as 45.1 months follow up. 
Volume reponse after GKS
Much of the previous studies concentrate on tumor’s volume
response following GKS. However, little is known about the
actual microbiological change that affects the volume response.
Benign tumors such as meningiomas, benign gliomas or sch-
wannomas have transient periods of volume expansion which
does not necessarily mean recurrence27). There are studies on
vestibular schwannomas that after gamma knife surgery, tra-
nsient increase in tumor volume is observed in 6~39% and
decrease after 3 months to 5 years follow up9,20,27,36). We also
noticed this transient volume expansion for craniopharyng-
iomas where transient volume expansion of tumor eventually
decreased at follow up imaging (case 1 and case 14). This
volume expansion was found to be as much as 200% of the
original tumor volume, but fortunately did not produce neu-
rological dysfunction thus enabling further observation. Wh-
atever the cause may be, clinicians should be aware that inc-
reased volume response does not necessarily mean recurrence
and should be open for observation until definite evidence
of recurrence emerges. 
Proper prescription dose between tumor control
and optic pathway sparing 
Majority of postoperative recurrence of craniopharyngiomas
locate at optic apparatus and hypothalamus17,31). This reflects
the difficulty of total resection of tumor in these adjacent
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Table 3. The results of gamma knife radiosurgery for craniopharygiomas reported in the literature
Authors Number of Mean or median Margin dose Control rate (%) Follow-up (years)
Patients/tumors volume (cm3) (Gy)
Prasad28) 338 ?.33 5-30 88.3 0.5-43
Mokry22) 323 8.33 9-15.4 74.3 2.33
Kobayashi19) 100 5.83 11.5 77.3 5.46
Chung10) 331 9.33 9.5-16 87.3 2.73
Chiou8) 10/12 1.35 16.4 58.3 5.25
Ulfarsson32) 21/22 7.83 <3-25 33.3 7.53
Kim18) 318 2.73 17.6 (4-35) 72.2 4.93
Barua4) 337 ?.33 14.2 83.3 5.33
Present 14/16 3.63 12.2 (8-22.4) 87.5 3.73
structures and importance of GKS adjacent to optic chiasm.
Studies demonstrated tolerance of 8 to 12Gy with incidence
of radiation optic neuropathy as low as 0~1.8%11,14). Kobayashi
et al19) used margin dose of 12.8Gy and gradually reduced
margin dose to 11.5Gy, suggesting the optimal dose to be
between 11 and 12Gy. Chung et al10) demonstrated com-
parable tumor control of 87.2% with use of 9 to 12Gy margin
dose. Study of Ulfarsson et al32) found out that margin dose
less than 6Gy is suboptimal, and tumor progression rate was
as high as 85%. They demonstrated statistically significant
difference with cases using 6Gy or more where tumor prog-
ression was 33%. Considering the minimal dose to optic app-
aratus to achieve tumor control without complication, 3 of
our cases where margin dose of 8 and 8.5Gy were used pro-
vided adequate tumor control as long as 98 months (mean
78.2 months). Although Ulfarsson32) recommended optimal
dose to be 6Gy or more, we recommend marginal dose of 8
to 8.5Gy for maximal tumor control and minimal radiation
related complication. 
The exact pathophysiology behind recurrence of craniop-
haryngiomas after GKS is yet to be proven. In our study, target
volume, nature of tumor and radiation dose did not provide
reason behind recurrence of craniopharyngiomas. However,
our study shares with previous reports that tendency of recu-
rrence rate increases after longer follow up period. This implies
that GKS for craniopharyngiomas is not yet a curative mod-
ality but a modality for control of tumor. Long term clinical
and imaging follow up is mandatory for optimal treatment
of tumor.
Conclusion
A s difficult as treatment of craniopharyngiomas can be,many diverse tactics of treatment are being conducted.
Less aggressive surgical removal and GKS seem to be effective
treatment modality regardless of nature of tumor whether it’s
cystic or solid. Dose of 8 to 8.5Gy may be sufficient to achieve
long term tumor control for craniopharyngiomas. 
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Commentary
T his is an attractive review about long term effect (mean3.7 years, ranging 1 to 10 years) of GKS for 14 cases of
remnant or recurred craniopharyngiomas on tumor control
and about suggesting proper radiation dose (8~8.5Gy) both
for tumor control and preserving the nearby crucial structures
(optic apparatus and hypothalamus).     
Craniopharyngiomas, pathologically benign but clinically
malignant neoplasia owing to their inevitable recurrence, im-
pose considerable challenges on the operators who wish to
remove tumors as much as possible while without residual
deficits. In most cases, the primary cause for incomplete removal
is a lack of anatomical dissection plane between tumor and
the hypothalamus or optic apparatus. Concern for hypothalamic
dysfunction or optic neuritis would also arise from radiation
to these regions, irrespective of detailed delivery methods (whole
brain irradiation, brachytherapy or GKS). Margin dose, sho-
wing maximum effect to withhold tumor regrowth whereas
showing minimum adverse effect to the adjacent structures,
has to be individualized, therefore. Eight to 8.5Gy, as suggested
in this review, appears as a little bit smaller than any previous
articles2,3). In this point of view, it is very fortunate that your
results showed very low rate of morbidity and I want to know
the reason more specifically.  
Authors have written that target volume, tumor nature (solid
or cystic) and radiation dose did not seem to affect the post-
operative recurrence for craniopharyngiomas. I agree with this
conclusion in some aspects, however, due to the small cohort
number and random allocation (tumor nature, individual
surgical approach, main complaints), external validity and
statistical verification (such as reducing type 2 error) should
be established by multi-center prospectively designed study
and enrolling a large volume of patients in near future. It is
generally believed that the longer the follow up period, the
more the number of recurrence after GKS (decrease in rate
of tumor control)1,4). I think the accumulated effect of radiation
has been diminished as time went by (i.e. more than 5 years
post-GKS). For this reason, I’m on the same side with you that
GKS for craniopharyngiomas is not yet a definite, curative
method for tumor control especially only in a certain limited
period of time. 
I want to address congratulation on your excellent clinical
outcome. 
Suck Jun Oh, M.D., Ph.D.
Department of Neurosurgery, Hanyang University 
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